These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26214803)

  • 41. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
    Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
    Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion.
    Noma H; Funatsu H; Mimura T; Harino S; Sone T; Hori S
    Acta Ophthalmol; 2010 Sep; 88(6):646-51. PubMed ID: 19563372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
    JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema.
    Noma H; Mimura T; Yasuda K; Shimura M
    Invest Ophthalmol Vis Sci; 2014 Jun; 55(6):3878-85. PubMed ID: 24894397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion.
    Campochiaro PA; Bhisitkul RB; Shapiro H; Rubio RG
    Ophthalmology; 2013 Apr; 120(4):795-802. PubMed ID: 23260261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cotton Wool Spots after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Associated with Central Retinal Vein Occlusion.
    Kida T; Tsujikawa A; Muraoka Y; Harino S; Osaka R; Murakami T; Ooto S; Suzuma K; Morishita S; Fukumoto M; Suzuki H; Ikeda T
    Ophthalmologica; 2016; 235(2):106-13. PubMed ID: 26800210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
    Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion.
    Gokce G; Sobaci G; Durukan AH; Erdurman FC
    Postgrad Med; 2013 Sep; 125(5):51-8. PubMed ID: 24113663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
    Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
    Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes of inflammatory factors after intravitreal triamcinolone acetonide for macular edema with central retinal vein occlusion.
    Noma H; Funatsu H; Mimura T
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):363-5. PubMed ID: 23046435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aqueous levels of VEGF correlate with retinal non-perfusion areas in patients with diabetic macular edema and macular edema secondary to central retinal vein occlusion.
    Machalinska A; Mozolewska-Piotrowska K; Czepita M; Spoz W; Dzieciolowska M; Kubasik-Kladna K; Szmatloch K; Lubinski W; Safranow K; Pius-Sadowska E
    Klin Oczna; 2016 Sep; 117(4):225-229. PubMed ID: 29727107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion.
    Park SP; Ahn JK
    Clin Exp Ophthalmol; 2008 Dec; 36(9):831-5. PubMed ID: 19278477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion.
    Noma H; Funatsu H; Yamasaki M; Tsukamoto H; Mimura T; Sone T; Hirayama T; Tamura H; Yamashita H; Minamoto A; Mishima HK
    Eye (Lond); 2008 Jan; 22(1):42-8. PubMed ID: 16826241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):615-21. PubMed ID: 21823986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion.
    Yasuda S; Kondo M; Kachi S; Ito Y; Terui T; Ueno S; Terasaki H
    Retina; 2011 Jun; 31(6):1075-82. PubMed ID: 21478810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of Novel Inflammatory Factors in Central Retinal Vein Occlusion with Macular Edema.
    Yasuda K; Noma H; Mimura T; Nonaka R; Sasaki S; Ofusa A; Shimura M
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38276038
    [No Abstract]   [Full Text] [Related]  

  • 59. Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular edema.
    Noma H; Mimura T; Masahara H; Shimada K
    Retina; 2014 Feb; 34(2):352-9. PubMed ID: 23842103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Six Months Outcome in Patients with Macular Edema Due to Retinal Vein Occlusion Treated with Ranibizumab].
    Sakanishi Y; Ouchi A; Ito R; Ebihara N
    Nippon Ganka Gakkai Zasshi; 2016 Jan; 120(1):28-34. PubMed ID: 26950966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.